期刊文献+

利伐沙班合成工艺改进

Improvement of Synthesis Process of Rivaroxaban
下载PDF
导出
摘要 目的:改进利伐沙班的合成工艺,满足产业化生产的要求。方法:以(S)-N-(2,3-环氧丙基)邻苯二甲酰亚胺和4-(4-氨基苯基)-3-吗啉酮为原料,经过缩合、环合、水解、酰化等反应,最终合成利伐沙班。结果:研究以甲磺酸代替原专利中的盐酸合成利伐沙班中间体4-[4-[(5S)-5-(氨甲基)-2-羰基-3-唑烷基]苯基]-3-吗啡啉酮甲磺酸盐,对于路线中的水解、酰化和最终的精制产品的步骤进行了优化,使产品的收率达到96.86%。结论:优化后的工艺改善了原研路线中存在的问题和不足,从而极大地提高了操作的安全性以及可行性,更加满足产业化生产的要求。 Objective:To improve the synthesis process of rivaroxaban while avoiding the patent protection of rivaroxaban.Methods:(S)-(+)-N-(2,3-Epoxypropyl)phthalimide and 4-(4-aMinophenyl)Morpholin-3-one were used as raw materials for the final synthesis of rivaroxaban through condensation,cyclization,hydrolysis and acylation reactions.Results:In the study,the methanesulfonic acid was used instead of hydrochloric acid to synthesize the rivaroxaban intermediate 4-[4-[(5S)-5(aminomethyl)-2-carbonyl-3-azolidinyl]phenyl]-3-morpholinone methanesulfonate,avoiding patent protection.Also,the steps of hydrolysis,acylation and the final refined product in the route were optimized to achieve a product yield of 96.86%.Conclusion:The optimized process not only avoids the problems of patent protection in the original route,but also improves the problems in the original route,thus greatly improving the safety and feasibility of the operation,and better meeting the requirements of industrial production.
作者 刘玉键 付新悦 周微 白万富 LIU Yujian;FU Xinyue;ZHOU Wei;BAI Wanfu(School of Pharmacy,Baotou Medical College,Baotou 014040,China;Tianshili Holding Group Limited Research Institute Chemical Development Center)
出处 《包头医学院学报》 CAS 2022年第12期76-80,共5页 Journal of Baotou Medical College
基金 内蒙古自治区自然科学基金项目(2021LHMS08013) 内蒙古自治区卫生健康科技计划项目(202202226) 包头医学院博士科研启动基金(BSJJ201814) 包头医学院硕士研究生科研创新资助项目(bycx2021009) 自治区大学生创新创业训练计划项目(S202119127004)。
关键词 利伐沙班 利伐沙班中间体 甲磺酸 原研路线 工艺优化 Rivaroxaban Rivaroxaban intermediate Patent protection Process optimization
  • 相关文献

参考文献3

二级参考文献40

  • 1Pinto DJ, Smallheer JM, Cheney DL, et al. Factor Xa Inhibitors: next-Generation Antithrombotic Agents [J]. J Med Chem, 2010, 53(17): 6243-74.
  • 2Blossom DB, Kallen A J, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin [J]. N Engl J Med, 2008, 359(25): 2674-84.
  • 3Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence based clinical practice guidelines (8th edition)[J]. Chest, 2008, 133(6): 160-98.
  • 4Brandstetter H, Ktihne A, Bode W, et al. X-ray struc- ture of active site-inhibited clotting factor Xa implica- tions for drug design and substrate recognition[J]. J Bi- ol Chem, 1996, 271(47): 29988-92.
  • 5Leadley J. Coagulation factor Xa inhibition: biological background and rationale [J]. Curr Top Med Chem, 2001, 1(2): 151-9.
  • 6Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting en- zyme complexes[J]. Ann Rev Biochem, 1988, 57: 915- 56.
  • 7陈旭华,梁岩,杨艳敏,等.新一代抗血栓药物Fonda-pafinux磺达肝癸钠[J].中国心脏病学杂志,2007,7(5):300-3.
  • 8Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 366(1): 9-19.
  • 9Shantsila E, Lip G. Apixaban, an oral, direct inhibitor of activated Factor Xa [J]. Curr ()pin Investigat Drugs, 2008, 9(9): 1020-33.
  • 10Camm AJ, Bounameaux H. Edoxaban [J]. Drugs, 2011, 71(12): 1503-26.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部